Deepinder Goyal, the visionary behind India’s food-tech giant Zomato, is making a bold pivot from food delivery to brain health. His latest venture, Temple, is developing a wearable device that tracks brain blood flow in real time. The startup recently raised $54 million in its first funding round, achieving a valuation of around $190 million—a striking vote of confidence in an unproven technology.
From Canteen Menus to Forehead Patches
Goyal’s entrepreneurial journey began in 2008 when he and a colleague noticed office workers queuing to see lunch menus. That observation led to Foodiebay, which later became Zomato—a public company and India’s first consumer tech unicorn. In early 2026, just weeks after stepping down as Zomato’s CEO, Goyal appeared on a podcast wearing a small forehead device called Temple. It wasn’t a gimmick; it was the prototype of his new startup.
How Temple Works
Temple’s product is a small, patch-like wearable that sticks to the temple or forehead. It claims to continuously monitor cerebral blood flow, similar to how fitness trackers measure heart rate or Oura rings track sleep. The ultimate goal: to help slow down aging by improving brain blood flow. Goyal has shared this theory online, but the science remains unverified and has not been peer-reviewed. Medical experts are skeptical, but investors are willing to bet on Goyal’s track record.
Investor Confidence and Risks
The $54 million round was led by Goyal’s long-time backers—Peak XV Partners (formerly Sequoia India), Info Edge, Steadview Capital, and Nikhil and Nithin Kamath of Zerodha. These investors saw Goyal turn a simple menu directory into a multi-billion-dollar business. Now they’re backing his foray into biotech and longevity, a field far riskier than food delivery. Goyal himself describes the move as “higher-risk exploration and experimentation.”
A New Chapter for Indian Tech
Temple is still in development. The company is running third-party studies to validate its metrics and recruiting early adopters to refine the technology. A consumer launch is expected within months. If successful, Temple could revolutionize how athletes monitor performance and how everyday people track brain health. If it fails, it will still be a landmark story—the moment one of India’s most celebrated founders bet his reputation not on food, but on the flow of blood through the human brain.
Temple operates independently from Goyal’s other ventures, including Continue (a health-tech project), LAT Aerospace, and Zomato’s parent company Eternal. As Indian tech evolves, Temple signals that the next big innovation may not come from delivery apps but from a small device that sticks to your forehead and tries to read your brain.
